androgen receptor

Protein · UniProt

Androgen receptor

Gene

AR

Organism

Homo sapiens (Human)

Length

920 aa

Molecular mass

99,188 Da

Evidence

1: Evidence at protein level

Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues (PubMed:19022849). Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3…

• Androgen Receptor in Hormone Receptor-Positive Breast Cancer.International journal of molecular sciences · 2023
• Basics of androgen synthesis and action.Best practice & research. Clinical endocrinology & metabolism · 2022
• Testosterone and the Androgen Receptor.The Urologic clinics of North America · 2022
• Androgen receptor: A promising therapeutic target in breast cancer.Critical reviews in clinical laboratory sciences · 2019
• Current androgen receptor antagonists under investigation for resistant prostate cancer.Expert review of anticancer therapy · 2022

via PubMed

• PHASE2COMPLETED
  Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerNational Cancer Institute (NCI) · NCT01875250
• PHASE3ACTIVE_NOT_RECRUITING
  An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Novartis Pharmaceuticals · NCT04720157
• PHASE2WITHDRAWN
  STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway SignalingToni Choueiri, MD · NCT01368003
• NARECRUITING
  START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPCInstituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · NCT05209243
• PHASE2ACTIVE_NOT_RECRUITING
  An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCNovartis Pharmaceuticals · NCT06894511
• PHASE3RECRUITING
  A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerJiangsu HengRui Medicine Co., Ltd. · NCT07311694

via ClinicalTrials.gov